eli lilly tirzepatide news today recency 3 recency:3 Tirzepatide Shows Superior Weight Loss Over Semaglutide in Phase Trial Eli Lilly plans diabetes drug
Description
ABSTRACT Objective SURMOUNTMAINTAIN aims to evaluate the efficacy and safety of reducing the tirzepatide dose and/or continuing the maximum tolerated dose (MTD) versus placebo in maintaining body weight (BW) reduction achieved with tirzepatide MTD
Yes, it is
Our healthcare providers at Primary Care of Clear Lake are excited to offer this advanced treatment option to support patients in achieving their health goals
Restaurant meals average 50-100% more sodium than home-cooked equivalents
Dissatisfied with Current Provider The Problem: Current doctor not supportive of weight loss goals Poor communication or follow-up Long wait times for appointments Want provider specializing in weight management The Solution: Switching to alternative through weight loss-focused telehealth platform provides specialized care
The medication received FDA approval for chronic weight management in adults with obesity on November 8, 2023 [1]
